Literature DB >> 30582672

Characterization of platelet factor 4 amino acids that bind pathogenic antibodies in heparin-induced thrombocytopenia.

Angela Huynh1, Donald M Arnold1,2,3, John G Kelton1, James W Smith1, Peter Horsewood1, Rumi Clare1, Alba Guarné4, Ishac Nazy1,2.   

Abstract

Essentials Many patients produce antibodies but few lead to heparin-induced thrombocytopenia (HIT). Pathogenic epitopes are difficult to identify as HIT antibodies are polyclonal and polyspecific. KKO binding to platelet factor 4 (PF4) depends on 13 amino acids, three of which are newly observed. Five amino acids in PF4 can help distinguish pathogenic from non-pathogenic antibodies.
SUMMARY: Background Heparin-induced thrombocytopenia (HIT) is an adverse drug reaction that results in thrombocytopenia and, in some patients, thrombotic complications. HIT is mediated by antibodies that bind to complexes of platelet factor 4 (PF4) and heparin. The antigenic epitopes of these anti-PF4/heparin antibodies have not yet been precisely defined, because of the polyspecific immune response that characterizes HIT. Objectives To identify PF4 amino acids essential for binding pathogenic HIT antibodies. Methods Alanine scanning mutagenesis was utilized to produce 70 single point mutations of PF4. Each PF4 mutant was used in an enzyme immunoassay (EIA) to test their capacity to bind a platelet-activating murine monoclonal anti-PF4/heparin antibody (KKO) and HIT patient sera (n = 9). Results and Conclusions We identified 13 amino acids that were essential for binding KKO because they directly affected either the binding site or the antigenic conformation of PF4. We also identified 10 amino acids that were required for the binding of HIT patient sera and five of these amino acids were required for binding both KKO and the HIT patient sera. The 10 amino acids required for binding HIT sera were further tested to differentiate pathogenic HIT antibodies (platelet activating, n = 45) and non-pathogenic antibodies (EIA-positive but not platelet activating, n = 28). We identified five mutations of PF4 that were recognized to be essential for binding pathogenic HIT antibodies. Using alanine scanning mutagenesis, we characterized possible binding sites of pathogenic HIT antibodies on PF4.
© 2018 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  CXCL4; heparin; heparin-induced thrombocytopenia; platelet factor 4; thrombocytopenia; thrombosis

Mesh:

Substances:

Year:  2019        PMID: 30582672     DOI: 10.1111/jth.14369

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  7 in total

1.  Monoclonal and oligoclonal anti-platelet factor 4 antibodies mediate VITT.

Authors:  Adam J Kanack; Antonios Bayas; Gemlyn George; Mouhamed Yazan Abou-Ismail; Bandana Singh; Mindy C Kohlhagen; Noah P Splinter; Monika Christ; Markus Naumann; Karen A Moser; Kristi J Smock; Alison Grazioli; Renren Wen; Demin Wang; David L Murray; Anand Padmanabhan
Journal:  Blood       Date:  2022-07-07       Impact factor: 25.476

Review 2.  Structural Features and PF4 Functions that Occur in Heparin-Induced Thrombocytopenia (HIT) Complicated by COVID-19.

Authors:  Zheng Cai; Mark I Greene; Zhiqiang Zhu; Hongtao Zhang
Journal:  Antibodies (Basel)       Date:  2020-10-10

3.  Vaccine-induced prothrombotic immune thrombocytopenia without thrombosis may not require immune modulatory therapy: A case report.

Authors:  Chieh Min Benjamin Lai; Agnes Y Y Lee; Stephen B I Parkin
Journal:  Res Pract Thromb Haemost       Date:  2022-05-18

4.  Hypotheses behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination.

Authors:  Jonathan Douxfils; Julien Favresse; Jean-Michel Dogné; Thomas Lecompte; Sophie Susen; Charlotte Cordonnier; Aurélien Lebreton; Robert Gosselin; Pierre Sié; Gilles Pernod; Yves Gruel; Philippe Nguyen; Caroline Vayne; François Mullier
Journal:  Thromb Res       Date:  2021-05-15       Impact factor: 3.944

5.  Anti-PF4 VITT antibodies are oligoclonal and variably inhibited by heparin.

Authors:  B Singh; A Kanack; A Bayas; G George; M Y Abou-Ismail; M Kohlhagen; M Christ; M Naumann; K Moser; K Smock; A Grazioli; D Murray; A Padmanabhan
Journal:  medRxiv       Date:  2021-09-24

6.  SARS-CoV-2 spike-dependent platelet activation in COVID-19 vaccine-induced thrombocytopenia.

Authors:  Jacob Appelbaum; Donald M Arnold; John G Kelton; Terry Gernsheimer; Stefan D Jevtic; Nikola Ivetic; James W Smith; Ishac Nazy
Journal:  Blood Adv       Date:  2022-04-12

Review 7.  The COVID Complex: A Review of Platelet Activation and Immune Complexes in COVID-19.

Authors:  Stefan D Jevtic; Ishac Nazy
Journal:  Front Immunol       Date:  2022-03-14       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.